Obesity

New-generation GLP-1 drugs, such as retatrutide, are achieving higher rates of weight loss. How much weight is too much and too fast to lose?

While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors

A growing body of research suggests that GLP-1 drugs do more than control appetite and blood sugar. They could also fight inflammation

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications

A new study suggests that people with obesity have higher rates of mortality and hospitalization from a variety of infections from viruses, fungi, parasites and bacteria

New WHO guidance calls for a worldwide obesity treatment “ecosystem” to ensure that GLP-1 weight-loss drugs are used fairly

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority of people who use these drugs quit after just two years

Instead of using the controversial body mass index, or BMI, to assess weight, an international group of scientists proposes an approach that looks at how excess body fat affects health

Whole grains and fruits are in, and added sugar is out. That’s going to change what’s on a lot of cereal boxes and other things

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?